U 101033E

Drug Profile

U 101033E

Latest Information Update: 03 Jan 2001

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Anti-inflammatories; Antiasthmatics; Neuroprotectants
  • Mechanism of Action Antioxidants; Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Stroke

Most Recent Events

  • 03 Jan 2001 No-Development-Reported for Asthma in USA (Unknown route)
  • 03 Jan 2001 No-Development-Reported for Stroke in USA (Unknown route)
  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top